BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)


| Study or Subgroup | Sacubitril/valsartan Events | Sacubitril/valsartan Total | Control Events | Control Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| AWAKE-HF 2019 | 0 | 70 | 1 | 70 | 0.1% | 0.33 [0.01, 8.04] |
| CLCZ696B2223 | 0 | 8 | 0 | 8 | | Not estimable |
| EVALUTE-HF 2019 | 1 | 232 | 2 | 233 | 0.1% | 0.50 [0.05, 5.50] |
| Li J 2019 (1) | 3 | 62 | 5 | 64 | 0.4% | 0.62 [0.15, 2.48] |
| OUTSTEP-HF | 1 | 310 | 5 | 311 | 0.2% | 0.20 [0.02, 1.71] |
| PARADIGM-HF 2014 | 729 | 4209 | 852 | 4233 | 97.8% | 0.86 [0.79, 0.94] |
| PIONEER-HF 2018 | 10 | 443 | 18 | 444 | 1.3% | 0.56 [0.26, 1.19] |
| PRIME-HF 2019 | 1 | 60 | 0 | 58 | 0.1% | 2.90 [0.12, 69.81] |
| **Total (95% CI)** | | **5394** | | **5421** | **100.0%** | **0.85 [0.78, 0.93]** |
| Total events | 745 | | 883 | | | |

Heterogeneity: Tau² = 0.00; Chi² = 4.30, df = 6 (P = 0.64); I² = 0%
Test for overall effect: Z = 3.56 (P = 0.0004)